Sudan Loganathan
Stock Analyst at Stephens & Co.
(0.74)
# 3,781
Out of 4,840 analysts
35
Total ratings
26.92%
Success rate
-20.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.32 | +1,483.78% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.49 | +253.36% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $24.49 | +34.75% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $2.43 | +229.22% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $18.84 | +165.39% | 2 | Feb 14, 2025 | |
| EXEL Exelixis | Reiterates: Equal-Weight | $29 | $42.39 | -31.59% | 4 | Feb 12, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $8.05 | +86.34% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $9.72 | +218.93% | 3 | Jan 21, 2025 | |
| KYMR Kymera Therapeutics | Reiterates: Overweight | $60 | $29.50 | +103.39% | 2 | Jan 21, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Overweight | $140 | $101.50 | +37.93% | 2 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.64 | +204.88% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.38 | +189.86% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $6.51 | +744.85% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.23 | +956.91% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $16.11 | +55.18% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.29 | +1,604.74% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.97 | +915.23% | 1 | May 14, 2024 |
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.32
Upside: +1,483.78%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.49
Upside: +253.36%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.49
Upside: +34.75%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $2.43
Upside: +229.22%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $18.84
Upside: +165.39%
Exelixis
Feb 12, 2025
Reiterates: Equal-Weight
Price Target: $29
Current: $42.39
Upside: -31.59%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $8.05
Upside: +86.34%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $9.72
Upside: +218.93%
Kymera Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $29.50
Upside: +103.39%
Blueprint Medicines
Jan 2, 2025
Reiterates: Overweight
Price Target: $140
Current: $101.50
Upside: +37.93%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.64
Upside: +204.88%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.38
Upside: +189.86%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $6.51
Upside: +744.85%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.23
Upside: +956.91%
Aug 6, 2024
Reiterates: Overweight
Price Target: $25
Current: $16.11
Upside: +55.18%
May 24, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.29
Upside: +1,604.74%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.97
Upside: +915.23%